Class: Blood Derivatives
ATC Class: B05AA01
VA Class: BL500
CAS Number: 9048-46-8
Brands: Albuminar, AlbuRx, Albutein, Buminate, Flexbumin, Plasbumin
Uses for Albumin Human
Used for plasma volume expansion and maintenance of cardiac output (fluid resuscitation) in the emergency treatment of hypovolemia (with or without shock) when urgent restoration of blood volume is indicated.187 204 205 206 207 208 210 211 212 213 214 215 218 220 221 226 227 254 255 256 295 297 300 301 303 304
Albumin human, a protein colloid, is one of several options that can be used to restore effective circulating volume; other options include nonprotein colloids (e.g., hetastarch, dextran) and large volume crystalloids (e.g., lactated Ringer's, various sodium chloride-containing solutions).148 187 219 222 225 226 227 228 304 308
Albumin human should not be considered a substitute for blood or blood components when oxygen-carrying capacity is reduced and/or when replenishment of clotting factors or platelets is necessary.134 170 187 Transfusion with whole blood or packed RBCs is required in patients with active hemorrhage and/or substantial anemia.204 205 207 208 210 211 214 215
Controversy exists regarding optimum choice of fluid (i.e., crystalloids, albumin human, nonprotein colloids) for fluid resuscitation.148 187 219 220 222 225 226 227 228 261 299 303 304 308 Protocols used, including type of replacement fluid, vary widely among health-care facilities148 187 219 220 222 225 226 227 228 261 303 304 308 and may depend on geographic area (e.g., country).304
Theoretical advantages of colloids include greater retention in the intravascular space, more effective and rapid plasma volume expansion, and reduced risk of pulmonary edema.187 211 214 220 225 226 227 228 However, colloids generally have not been shown to be more effective than crystalloids, and costs associated with colloids are substantially higher than those associated with crystalloids.148 187 219 220 222 225 226 228
Based on current evidence, albumin human appears to offer no survival advantage over crystalloids for fluid resuscitation; possibility of a modest benefit or harm cannot be excluded.187 218 219 222 225 Additional studies needed to determine role of albumin human in selected patient populations.218 219 222 224 225
Guidelines on use of albumin, nonprotein colloids, and crystalloids issued in 2000 by the US University Health System Consortium (UHC) state that crystalloids are preferred for initial fluid resuscitation in adults with hemorrhagic shock.187 Nonprotein colloids may be considered when crystalloids (4 L) fail to produce an adequate response within 2 hours; albumin human 5% solution may be considered if nonprotein colloids are contraindicated.187
Nonhemorrhagic (Maldistributive) Shock
UHC guidelines state that crystalloids should be considered first-line therapy in adults with nonhemorrhagic (maldistributive) shock and that nonprotein colloids and albumin human should be used with caution in those with systemic sepsis.187 In the presence of capillary leak with pulmonary and/or severe peripheral edema, use of up to 4 L of crystalloid solution is appropriate before using colloids.187 If albumin human is used for acute management of nonhemorrhagic shock, consider possibility of a potentially detrimental effect on edema in patients with increased capillary permeability or capillary leak.152 168 187
Other experts state that either crystalloids or colloids can be used for fluid resuscitation in patients with septic shock.250 251 261 295 297 300 Although there is some evidence that adult or pediatric patients with severe infection and shock who receive albumin human have lower mortality compared with those who receive crystalloids,222 261 297 299 300 prospective, randomized studies are needed to clearly identify which type of fluid is superior for fluid resuscitation in patients with septic shock.250 251 261 297 298 299 300
Fluid resuscitation is an essential component of burn therapy,187 306 but optimum regimen of crystalloids, colloids, electrolytes, and fluid not clearly established.204 205 207 208 211 213 214 215 218 302 305 306 307 309
Crystalloids generally recommended for initial fluid resuscitation during first 24 hours following thermal injury.187 204 205 207 211 213 214 309 Beyond 24 hours, colloids may be used in conjunction with crystalloids to prevent hemoconcentration, combat electrolyte imbalances, and counteract protein deficits.204 205 207 208 210 211 213 214 215 309 To avoid complications of over-resuscitation (“fluid creep”), such as abdominal compartment syndrome and ARDS, use minimal amount of fluid necessary to maintain adequate organ perfusion.305 306 307 309
UHC guidelines recommend crystalloids for initial fluid resuscitation in adults with thermal injury, but state that nonprotein colloids may be added if burns extend over >30% of body surface area and if >4 L of crystalloid has been administered 18–26 hours following initial injury; albumin human may be considered if nonprotein colloids are contraindicated.187
Guidelines issued by the American Burn Association state that the addition of colloids to burn resuscitation protocols may be beneficial in terms of decreasing total fluid volume requirements, but randomized, controlled trials are needed to clearly establish other benefits.307
In pediatric burn patients, albumin human does not appear to decrease morbidity and mortality187 and, depending on the preparation used, may result in aluminum accumulation in infants.140 143 144 187 (See Aluminum Content under Cautions.)
Nephrosis and Nephrotic Syndrome
Cardinal features of nephrotic syndrome include albuminuria, hypoalbuminemia, and edema.187 Decreased hepatic production and increased renal catabolism are responsible for hypoalbuminemia and renal sodium retention is responsible for edema.187
UHC guidelines recommend short-term adjunctive use of albumin human with diuretics in adults with nephrotic syndrome who have acute, severe peripheral and/or pulmonary edema unresponsive to diuretics alone;187 consider possibility of potentially detrimental effect on edema.152 168 187
Albumin human has no role in management of chronic nephrosis; parenteral albumin is rapidly excreted renally with no relief of chronic edema and no effect on the underlying renal lesion.134 204 205 213 214
Has been used as an adjunct to hemodialysis in long-term hemodialysis patients with oncotic or volume deficits or in those experiencing shock or hypotension who cannot tolerate substantial volumes of sodium chloride solution.204 205 206 212 214 261 265 266
Intradialytic hypotension, a complication of hemodialysis (especially in long-term hemodialysis patients), usually is managed by volume expansion through the use of crystalloids (e.g., 0.9% sodium chloride solutions, hypertonic sodium chloride solutions), nonprotein colloids, or albumin human.261 265 266
Although some experts recommend colloids for dialysis-related hypotension and maintenance of hemodynamics in chronic dialysis patients,261 others state that 0.9% sodium chloride solution should be considered first-line therapy for treatment of intradialytic hypotension in maintenance hemodialysis patients.265
UHC guidelines state that albumin human should not be used for intradialytic blood pressure support.187 If hemodialysis patients experience shock symptoms, crystalloids should be used for initial fluid resuscitation; nonprotein colloids may be considered if crystalloids (4 L) fail to produce an adequate response within 2 hours; albumin human 5% solution may be used if nonprotein colloids are contraindicated.187
Cirrhotic Ascites and Paracentesis
If tense ascites is present in new-onset disease, an initial large-volume paracentesis may be necessary in addition to sodium restriction and oral diuretics.236 286 In those with refractory ascites (fluid overload unresponsive to sodium restriction and high-dose oral diuretic therapy or that recurs rapidly after paracentesis), serial therapeutic paracentesis may be indicated to control ascites.236 287
A single paracentesis involving removal of ≤4–5 L of fluid usually can be performed safely without postparacentesis colloid support; when larger volumes (>5 L) are removed, use of albumin human may be considered and usually is recommended to decrease risk of postparacentesis circulatory dysfunction and maintain effective arterial blood volume.187 236 261 264 286 287
Although albumin human has been used alone (without large-volume paracentesis) in patients with cirrhosis in an attempt to control or prevent recurrence of ascites,187 236 285 236 guidelines from the American Association for the Study of Liver Diseases (AASLD) and UHC state that such use is notrecommended.187 236
Type I hepatorenal syndrome is characterized by acute, rapidly progressing renal failure caused by intrarenal vasoconstriction and usually requires liver transplantation if not reversed.236 244 286 287 288 289 293 294
Although additional study is needed, AASLD and other experts state that a regimen of albumin human used in conjunction with vasoconstrictors (e.g., terlipressin [not commercially available in the US], octreotide and midodrine, norepinephrine) should be considered in the treatment of type I hepatorenal syndrome†.236 264 289 294
Data are limited regarding use of albumin human alone or in conjunction with vasoconstrictors in the management of type II hepatorenal syndrome† (characterized by moderate and slowly progressive renal failure and typically associated with refractory ascites); additional study is needed to determine if albumin human has a role in this form of the disease.236 289 291 294
Spontaneous Bacterial Peritonitis
Spontaneous bacterial peritonitis is a complication that can occur in patients with cirrhosis and ascites, develops without a contiguous source of infection (e.g., intestinal perforation, intra-abdominal abscess), requires prompt empiric anti-infective therapy, and may result in potentially fatal, progressive renal impairment and/or hepatorenal syndrome.236 267 286 287 Although there is some evidence that adjunctive use of albumin human for volume expansion in addition to appropriate anti-infective treatment may decrease risk of renal impairment and death,236 261 267 268 269 286 such use is controversial and additional study is needed.187 267 268 269 270 289
AASLD recommends that albumin human be used in addition to appropriate anti-infective treatment (e.g., cefotaxime) in patients who have ascitic fluid polymorphonuclear (PMN) counts ≥250 cells/mm3 and also have S cr >1 mg/dL, BUN >30 mg/dL, or total bilirubin >4 mg/dL.236
Acute Liver Failure
May serve dual purpose of supporting plasma colloid osmotic pressure as well as binding excess plasma bilirubin in the uncommon situation of rapid loss of liver function, with or without coma.204 205 213
Has been used for postoperative fluid support in patients undergoing hepatic resection†.187 Surgical liver resection results in substantial blood loss and, depending on preoperative functional status of the liver, decreased albumin production capacity.187
UHC guidelines state that crystalloids are first-line therapy for maintenance of effective circulating volume following hepatic resection in adults; if crystalloids have no effect and anemia and/or coagulopathy are present, consider use of packed RBCs and fresh frozen plasma before use of albumin human.187
UHC guidelines state that albumin human is appropriate to maintain effective circulation volume following major (>40%) hepatic resection in adults and also is indicated if clinically important edema develops secondary to use of crystalloids.187
Has been used in management of severe hypoalbuminemia (with or without edema) in an attempt to restore serum albumin concentrations to within normal range.204 205 207 208 210 211 212 214 215 254 255 266 However, in the absence of clinically important hypovolemia, should not be used to correct temporary protein deficits resulting from redistribution of albumin.211 214 231
Hypoproteinemia (hypoalbuminemia) can occur in association with various clinical conditions (e.g., surgery, sepsis, chronic liver failure, chronic renal impairment) and is a result of inadequate production, increased catabolism, redistribution, and/or excessive loss of albumin.204 205 206 208 210 211 214 215 231
May relieve edema associated with hypoproteinemia by increasing colloid osmotic pressure and producing diuresis.207 214 However, there is potential risk of fluid overload if administered to normovolemic patients with hypoproteinemia.231
Not recommended for use in severe hypoalbuminemia in the absence of hypovolemia simply to increase serum albumin concentrations to normal; identify and treat cause of the underlying hypoalbuminemia instead.147 152
Should not be used for treatment of hypoproteinemia associated with chronic cirrhosis, chronic nephrosis, malabsorption, protein-losing enteropathies, pancreatic insufficiency, or malnutrition, unless a concomitant indication warrants use.204 205 211 213 214
Has been used to treat neonatal hypoalbuminemia†, but data are insufficient to determine whether routine use of albumin human reduces mortality or morbidity in preterm neonates with hypoalbuminemia.231
Albumin human may be beneficial for severe diarrhea (>2 L daily) associated with enteral feeding intolerance† when serum albumin concentration is <2 g/dL or if diarrhea occurs despite a trial of short-peptide and elemental formulas and other causes of diarrhea have been excluded.134 148 177 187
Has been administered prior to exchange transfusion (as a primer) or during the procedure (as a substitute for a portion of the blood).187 204 205 208 214 215 Because there is some evidence that administration prior to exchange transfusion is less efficient in bilirubin removal and may increase the risk of volume overload, UHC guidelines recommend administration during the procedure if albumin human is used as an adjunct to exchange transfusion.187
Crystalloids and nonprotein colloids do not share the bilirubin-binding properties of albumin human and should not be considered alternatives for adjunctive treatment of neonatal hyperbilirubinemia.187
Used as a plasma expander for fluid management in women with severe ovarian hyperstimulation syndrome (OHSS).255 256 Albumin human 20 or 25% solutions have been recommended in the treatment of severe OHSS if 0.9% sodium chloride solutions fail to achieve or maintain hemodynamic stability and adequate urine output.238 255 256
Has been investigated for prevention of severe OHSS in high-risk women undergoing ovulation induction†.187 232 237 238 239 240 241 242 258 259 260 Additional study needed to more fully evaluate benefits and risks for prevention of OHSS.187 232 260 Although there is some evidence that administration of albumin human 20 or 25% solution immediately before or after oocyte retrieval can reduce the risk of severe OHSS in high-risk women (i.e., <35 years of age, multifollicular development, high serum estradiol concentrations, nonobesity, polycystic ovary disease),232 237 238 239 240 241 242 other studies failed to confirm such benefits.258 259 260
Acute Respiratory Distress Syndrome and Acute Lung Injury
Use in ARDS is controversial because of the risk of aggravating interstitial fluid accumulation and other possible detrimental pulmonary effects.134 171 172 173 177 Although uncertainty exists regarding the precise indication in patients with ARDS,208 214 215 261 some manufacturers state that albumin human may have a therapeutic effect if used in conjunction with a diuretic in patients with pulmonary overload accompanied by hypoalbuminemia.208 214 215
Has been used in conjunction with furosemide in the management of hypoproteinemic patients with acute lung injury† (ALI) and has resulted in improved oxygenation and hemodynamic stability in some patients.261 262 263 283 Some experts state that conservative fluid management or restriction is appropriate for most patients with hemodynamically stable ALI/ARDS,261 283 284 283 but a regimen of colloids and diuretics may be considered in those with hypo-oncotic ALI/ARDS.261 283
Sequestration of Protein Rich Fluids
Has been used for volume and oncotic replacement in conditions associated with sequestration of protein rich fluid (third-spacing) (e.g., acute peritonitis, pancreatitis, mediastinitis, extensive cellulitis).204 205 211 213 214
Has been used as an adjunct to anti-infectives in the treatment of spontaneous bacterial peritonitis† in patients with cirrhosis and ascites.187 236 267 268 269 286 (See Spontaneous Bacterial Peritonitis under Uses.)
May be useful in early treatment of shock associated with acute hemorrhagic pancreatitis or peritonitis.211
UHC guidelines state that albumin human is not recommended in the treatment of acute or chronic pancreatitis.187
Has been used as a pump prime for preoperative dilution of blood prior to cardiopulmonary bypass procedures,187 204 205 206 208 210 212 213 214 281 282 usually in conjunction with a crystalloid.187 204 205 213 214 215 282
UHC guidelines state that crystalloids alone are preferred for priming cardiopulmonary bypass pumps in adults, although use of nonprotein colloids in addition to crystalloids may be preferred when it is extremely important to avoid pulmonary shunting.187
Has been used in cardiac surgery patients to restore fluid balance during surgery and in the postoperative period;187 208 210 215 281 however, there are no data establishing clear benefit over crystalloids alone.187 208 210 215 For postoperative volume expansion after cardiac surgery in adults, UHC guidelines state that crystalloids are preferred, followed in descending order of preference by nonprotein colloids and then albumin human.187
Neurosurgery and Cerebral Injury
Has been used for hemodilution to maintain or improve cerebral perfusion in the treatment of subarachnoid hemorrhage†, acute ischemic stroke†, traumatic brain injury†, and in other neurosurgical patients†.174 175 176 187 261 272 273 274 275 276 277 278 279 280
Various fluid protocols have been used in an attempt to prevent secondary ischemia after subarachnoid hemorrhage, severe ischemic stroke, or severe traumatic brain injury; improved clinical outcomes reported in some patients.187 272 275 276 277 278 279 However, there is no clear evidence to date from adequately controlled, randomized studies that hemodilution decreases mortality or improves functional outcome in survivors of acute ischemic stroke.187 274
UHC guidelines state that crystalloids are preferred for maintenance of cerebral perfusion pressure in the treatment of cerebral vasospasm associated with subarachnoid hemorrhage, cerebral ischemia, or head trauma in adults, but albumin human 25% solution should be used if cerebral edema is a concern.187 Patients with elevated hematocrits should receive crystalloids first to increase intravascular volume, creating a state of hypervolemia and hemodilution; those with hematocrits <30% should receive packed RBCs to increase intravascular volume and maintain cerebral perfusion pressure.187 If volume therapy alone is inadequate to maintain cerebral perfusion pressure, vasopressor therapy may be necessary.187
Liver or Kidney Transplantation
Has been used to control ascites and severe pulmonary and peripheral edema in liver transplant recipients†.187 Because of excessive blood loss, volume expanders such as crystalloids, blood products, nonprotein colloids, and albumin human may be required intraoperatively during liver transplantation.187
UHC guidelines state that albumin human may be used in adult liver transplant recipients when serum albumin is <2.5 g/dL, pulmonary capillary wedge pressure is <12 mm Hg, and hematocrit is >30%.187
Has been used intraoperatively in conjunction with crystalloids for volume expansion in kidney transplant patients.148 187 However, there is no conclusive evidence from controlled, randomized studies that albumin human given during and/or after renal transplant surgery improves outcome.148 187
Used in conjunction with large-volume plasma exchange as protein volume replacement in plasmapheresis† procedures involving exchange of >20 mL of plasma/kg in one session or >20 mL/kg weekly in multiple sessions.148 187
UHC guidelines state that nonprotein colloids and crystalloids may substitute for some of the albumin human in therapeutic plasmapheresis† procedures and should be considered cost-effective exchange media.187
Has been used to resuspend large volumes of previously frozen or washed RBCs prior to administration or during certain types of exchange transfusion to provide sufficient volume and/or avoid excessive hypoproteinemia during the transfusion.204 205 214
Albumin Human Dosage and Administration
Albumin human 20 or 25% solutions: May be preferred in patients with oncotic deficits or in those with long standing hypovolemia and hypoalbuminemia that exists in the presence of adequate or excessive hydration.204 205 208 210 215 Also recommended when albumin human is used for its binding rather than oncotic properties (e.g., treatment of neonatal hyperbilirubinemia).204 205 206 208 211 212 214 215
When used for treatment of hypovolemia, most effective in well-hydrated patients.208 215 254 255 256 If patient is dehydrated, albumin human 5% solution usually preferred;204 205 208 213 215 if albumin human 20 or 25% solution used in dehydrated patients, administer additional crystalloids or fluids.204 205 206 207 208 214 215
Consult manufacturers' prescribing information for specific directions regarding use of IV administration sets and filters.204 205 206 207 208 210 211 212 213 214 215 254 255 256 Some manufacturers state that adequate filtration is required;206 208 210 212 215 others state that filtration is not required.254 255 256
Depending on indication, protein and fluid requirements, sodium restrictions, and availability, commercially available albumin human solutions can be administered undiluted or can be further diluted in a compatible IV solution (e.g., 0.9% sodium chloride, 5% dextrose).37 124 125 126 127 128 129 130 131 132 133 134 135 136 137 184 204 205 206 207 208 214 215 For solution and drug compatibility information, see Compatibility under Stability.
Whenever dilution of albumin human is necessary, the oncotic and osmotic properties as well as the tonicity of the resultant dilution must be considered.37 124 125 126 127 128 129 130 131 132 133 134 135 136 137 184
Substantially hypotonic solutions when admixed with erythrocytes result in hemolysis.131 132 Such hemolysis occurs when erythrocytes are admixed in vitro with albumin human solutions containing less than 90 mEq of sodium per L;37 127 the sodium concentration not the suspending medium (albumin) or cell concentration determines the hemolytic risk.37 131 132
Because of risk of potentially life-threatening hemolysis and acute renal failure, do not dilute albumin human with sterile water since tonicity can be reduced substantially by such dilution.125 127 128 129 130 133 134 135 136 137 138 184 204 205 206 207 208 210 214 215 254 255 256 (See Oncotic, Osmotic, and Tonicity Considerations under Cautions.)
If necessary, albumin human 5% solutions may be prepared from albumin human 25% solutions by adding 1 volume of the 25% solution to 4 volumes of 0.9% sodium chloride or 5% dextrose.208 Since albumin human 25% solution diluted with 0.9% sodium chloride or 5% dextrose results in 5% dilutions that are approximately isotonic and iso-oncotic with citrated plasma, these diluents are preferred for such dilutions.133 136 137
Do not use dilutions with substantially reduced tonicity as replacement fluids in plasmapheresis procedures or other situations where administration of large volumes and resultant replacement of a significant fraction of blood volume could result.125 126 127 128 129 130 133 136 137 138 184
When sodium restriction is necessary, administer albumin human solutions either undiluted or diluted in sodium-free carbohydrate solution such as 5% dextrose.133 184 204 205 However, because administration of large volumes of albumin human 5% prepared by diluting 25% solutions with 5% dextrose could result in hyponatremia and potentially serious adverse effects (e.g., cerebral swelling),136 137 0.9% sodium chloride is the preferred diluent when administration, particularly rapid administration, of large volumes is anticipated (e.g., during plasmapheresis or plasma exchange) and the fluid and electrolyte status of the patient permits.136 137 184
Alternatively, more physiologic diluents (e.g., those closely resembling plasma) can be used to dilute albumin human for use in plasmapheresis or plasma exchange.136
Rate of Administration
Individualize rate of IV infusion based on indication, concentration of albumin human solution used, and patient's clinical status and response.204 205 206 207 208 210 211 212 213 214 215 254 255 256 Consult manufacturers’ prescribing information for specific recommendations.204 205 206 207 208 210 211 212 213 214 215 254 255 256
Albumin human 5% solution: When used for treatment of hypovolemic shock in patients with greatly reduced blood volume, a rapid rate of administration may be necessary initially to provide clinical improvement and restore normal blood volume.210 211 212 However, in patients with a history of cardiac or vascular disease, some manufacturers suggest a slow infusion rate (e.g., 5–10 mL/minute) to avoid too rapid a BP increase.210 In patients with normal or slightly low blood volume, some manufacturers suggest an infusion rate of 1–2 mL/minute.211 212
Albumin human 20 or 25% solutions: When used for treatment of hypovolemic shock in patients with greatly reduced blood volume, a rapid rate of administration may be necessary initially to provide clinical improvement and restore normal blood volume.206 However, in patients with normal or slightly low blood volume, some manufacturers state that the IV infusion rate should not exceed 1 mL/minute since more rapid infusion rates may result in circulatory overload or pulmonary edema.206 207 208 215 Slower rate also is recommended in patients with hypertension.207 When albumin human 20 or 25% solution is used in hypoproteinemic patients with approximately normal blood volume, a maximum rate of 2 mL/minute (Plasbumin-20, Plasbumin-25)204 205 or 2–3 mL/minute (Albuminar-25) has been recommended.207
Dosage is variable; individualize based on specific indication, concentration of albumin human solution used, and patient's clinical status and response.204 205 206 207 208 210 211 212 213 214 215 254 255 256 Consult manufacturers' prescribing information for specific dosage recommendations.204 205 206 207 208 210 211 212 213 214 215
Predetermined formulas for dosage calculation generally are avoided since they assume that the same dose is appropriate for all patients.187
In the absence of acute hemorrhage, total daily albumin dosage should not exceed the theoretical amount present in total normal plasma volume (i.e., 2 g/kg body weight).21 204 205 208 210 214 215 254 255 256
To assess response to therapy, monitor hemodynamic response (e.g., BP), degree of pulmonary congestion, and hematocrit.207 211 214 Measurement of serum protein usually not necessary, but may be useful to guide dosage selection in some cases of hypoproteinemia.214
Albumin human injection for IV infusion
100 mL of 5% solution (5 g)
100 mL of normal human plasma
100 mL of 20% solution (20 g)
400 mL of normal human plasma
100 mL of 25% solution (25 g)
500 mL of normal human plasma
0.5–1 g/kg is recommended by some clinicians.311
0.5–1 g/kg given over 0.5–2 hours and repeated once every 1–2 days as needed is recommended by some clinicians.311
Has been given prior to exchange transfusion (as a primer) or during the procedure (as a substitute for a portion of the blood).187 204 205 208 214 215 255 256 (See Neonatal Hyperbilirubinemia under Uses.)
For hypovolemic shock, some manufacturers recommend the following initial dose.206 208 210 211 212 215 254 255 256 Dose may repeated after 15–30 minutes if response is inadequate.206 208 210 211 212 215 254 255 256
Albumin human 20% solution: 25 g (125 mL of a 20% solution).255
Optimum regimen of crystalloids, colloids, electrolytes, and fluid not clearly established.204 205 207 208 211 213 214 215 218 302 305 306 307 309 Duration of replacement therapy varies, depending on such factors as extent of protein loss from renal excretion, denuded skin areas, and decreased albumin production.204 205 207 213 214
One manufacturer recommends use of large volumes of crystalloids initially to maintain plasma volume; after 24 hours, albumin human may be added.254 255 256 Initially, 25 g; adjust dosage thereafter to maintain a plasma protein concentration of 2.5 g/dL or serum protein concentration of 5.2 g/dL.254 255 256
Albumin human 20 or 25% solutions: If used for treatment of volume or oncotic deficit in patients undergoing long-term dialysis or for treatment of shock or hypotension in these patients, some manufacturers state that usual dose is about 100 mL204 205 (initial dose should not be >100 mL).214 Carefully monitor for signs of circulatory overload.204 205 212 214
Cirrhotic Ascites and ParacentesisIV
A single paracentesis involving removal of ≤4–5 L of fluid usually can be performed safely without colloid support; use of albumin human may be considered when larger volumes (>5 L) are removed.187 236 261 264 286 287
Hepatorenal Syndrome (Type I)†IV
Some experts recommend 1 g/kg (up to 100 g) on day 1, followed by 20–40 g once daily.289 293 294 If a response is obtained, continue until S cr <1.5 mg/dL.294 May discontinue if serum albumin >4.5 g/dL; discontinue if pulmonary edema is present.289
Spontaneous Bacterial Peritonitis†IV
AASLD recommends that adults with ascitic PMN counts ≥250 cells/mm3 and clinical suspicion of spontaneous bacterial peritonitis who also have S cr >1 mg/dL, BUN >30 mg/dL, or total bilirubin concentration >4 mg/dL receive 1.5 g/kg of albumin human within 6 hours of detection and 1 g/kg on day 3.236
Albumin human 5% solution: 50–75 g recommended by one manufacturer.254
Albumin human 20 or 25% solutions: 50–75 g daily (e.g., 250–375 mL of a 20% solution or 200–300 mL of a 25% solution) is recommended by some manufacturers;204 205 207 255 256 larger amounts may be required in those with severe hypoproteinemia who continue to lose albumin.204 205 Some manufacturers recommend a maximum dosage of 2 g/kg daily.208 210
Consider total body albumin deficit (including hidden extravascular albumin deficiency) when determining dosage necessary to reverse hypoalbuminemia.208 210 215 255 256 When using serum albumin concentrations to estimate protein deficit, calculate body albumin compartment based on 80–100 mL/kg to account for any hidden extravascular albumin deficits.208 210 215
Ovarian Hyperstimulation Syndrome (OHSS)
Treatment of Severe OHSSIV
Acute Respiratory Distress Syndrome
Albumin human 20 or 25% solutions: For management of fluid overload in conjunction with a diuretic (see Acute Respiratory Distress Syndrome and Acute Lung Injury under Uses), one manufacturer recommends 25 g given by IV infusion over 30 minutes and repeated at 8-hour intervals for 3 days, if necessary.255 256
Albumin human 20 or 25% solutions: If used to resuspend RBCs during certain types of exchange transfusion or to resuspend large volumes of previously frozen or washed RBCs, some manufacturers recommend adding approximately 20–25 g of albumin per liter of isotonic suspended RBCs immediately prior to transfusion;204 205 214 greater amounts may be required in patients with preexisting hepatic impairment or hypoproteinemia.204 205
Maximum 6 g/kg in 24 hours or 250 g in 48 hours recommended by some clinicians.311
Cautions for Albumin Human
Hypersensitivity to albumin,204 205 206 207 208 210 211 212 213 214 215 254 255 256 any ingredient in the formulation,254 255 256 or component of the container.254 255 256 (See Sensitivity Reactions under Cautions.)
Consider that certain individuals are at particular risk of circulatory overload, including those with stabilized chronic anemia, CHF, or renal insufficiency.204 205 213 (See Renal Impairment under Cautions.)
Buminate 25%: Contraindicated in patients with chronic renal impairment because of risk of aluminum accumulation.215 (See Aluminum Content under Cautions.)
Dilution with sterile water for injection contraindicated because of risk of potentially life-threatening hemolysis and acute renal failure.125 127 128 129 130 133 134 135 136 137 138 184 204 205 206 207 208 210 214 215 254 255 256 (See Oncotic, Osmotic, and Tonicity Considerations under Cautions.)
Risk of Transmissible Agents in Plasma-derived Preparations
Because albumin human is prepared from pooled human plasma, it is a potential vehicle for transmission of human viruses (e.g., hepatitis viruses, HIV) and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt-Jakob disease (CJD) or related agents such as variant CJD (vCJD).192 193 194 204 205 206 207 208 210 211 212 213 214 215 254 255 256
Donor plasma screening and viral elimination/inactivation procedures (e.g., pasteurization) have reduced, but not entirely eliminated risk of transmission of infectious agents.192 204 205 206 207 208 210 211 212 213 214 215 254 255 256
Risk of transmission of viral disease with plasma-derived albumin human is considered extremely remote.192 206 207 208 210 211 212 214 215 No causes of transmission of HBV, HCV, or HIV have been documented following use of commercially available albumin human.192 206 207 208 210 211 212 214 215 However, transmission of nonenveloped viruses, (e.g., hepatitis A virus [HAV] and parvovirus B19) has been documented following administration of plasma-derived coagulation factors.190
There are no documented cases of CJD or vCJD transmitted through plasma-derived preparations (including plasma-derived albumin human); theoretical risk for transmission of CJD with commercially available albumin human is considered extremely remote.120 121 122 123 191 192 193 206 207 208 210 211 212 214 215 There have been 3 probable cases of vCJD acquired through transfusion of RBCs.202 For further information on CJD and vCJD precautions related to blood and blood products, consult the FDA guidance for industry on this topic ().192
Transmission of West Nile Virus (WNV) through commercially available plasma-derived preparations is unlikely; WNV is an enveloped virus, like HCV, which is known to be inactivated by purification and viral elimination/inactivation procedures used in manufacture of these preparations.196 197 However, there is evidence that WNV can be transmitted in transplanted organs (e.g., heart, liver, kidney) and blood products (e.g., whole blood, packed RBCs, fresh frozen plasma).195 196 198 199 For further information on WNV precautions related to blood and blood products, consult the FDA guidance for industry on this topic ().196
Because no purification method has been shown to be totally effective in removing the risk of viral infectivity from plasma-derived preparations and because new blood-borne viruses or other disease agents may emerge which may not be removed or inactivated by current manufacturing processes, discuss risks and benefits of albumin human with patient.204 205 206 207 208 210 211 212 213 214 215
Hypersensitivity reactions reported, including anaphylaxis or anaphylactoid reactions,207 208 210 215 252 253 254 255 256 fever,204 205 206 207 208 210 211 212 213 214 215 254 255 256 chills,204 205 206 207 208 210 211 212 213 214 215 254 255 256 rash,206 207 212 254 255 256 urticaria,204 205 207 208 210 211 213 214 215 254 255 256 pruritus,207 254 255 256 angioneurotic edema,254 255 256 and erythema or flushing.207 254 255 256
If an allergic or hypersensitivity reaction (e.g., anaphylaxis) occurs or is suspected, discontinue immediately and initiate appropriate therapy as indicated.207 208 210 215 254 255 256 Epinephrine should be readily available in case acute hypersensitivity occurs.254 255 256
Some packaging components of certain albumin human preparations (e.g., Buminate 5%, Buminate 25%) may contain natural latex proteins.210 215 Take appropriate precautions if these preparations are administered to individuals with a history of latex sensitivity.233 234 235
Use with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk for the patient (e.g., decompensated cardiac insufficiency, hypertension, esophageal varices, pulmonary edema, hemorrhagic diathesis, severe anemia, renal and postrenal anuria).206 210 215 254 255 256
Use with caution in patients with low cardiac reserve (e.g., cardiac disease)204 205 206 207 212 and in those who do not have albumin deficiency.207 Use with great caution in patients with chronic anemia, hypertension, renal insufficiency, or severe pulmonary infections.206 207 211 214
At first clinical sign of possible cardiovascular overload (e.g., headache, dyspnea, increased BP, jugular venous distention, elevated central venous pressure, pulmonary edema), immediately discontinue albumin human infusion and reevaluate patient.210 254 255 256
In postoperative or injured patients, a rapid rise in BP following administration of albumin human may reveal bleeding points that were not apparent at lower BP.204 205 206 207 208 210 212 213 215 To prevent hemorrhage and shock, carefully observe such patients and treat appropriately.204 205 206 207 208 210 212 213 215
Anemia and Coagulation Abnormalities
If comparatively large volumes of fluid are being replaced with albumin human, monitor coagulation parameters and hematocrit; ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets, erythrocytes) when indicated.208 210 215 254 255 256
Oncotic, Osmotic, and Tonicity Considerations
When dilution of albumin human is necessary (e.g., to prepare a 5% solution from a 25% solution), the oncotic and osmotic properties as well as the tonicity of the resultant dilution must be considered.37 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 184
Several cases of hemolysis (e.g., during or after plasmapheresis) and at least one death probably related to hemolysis have been reported following administration of as little as 270 mL of an albumin human 5% solution that had been prepared extemporaneously by diluting a 25% solution with sterile water.124 125 126 127 129 130 133 138 184 Such dilutions are markedly hypotonic with respect to blood, with calculated resultant sodium concentrations of 26–32 mEq/L.124 125 126 127 129 130 133
Because of risk of potentially life-threatening hemolysis and acute renal failure, albumin human must not be diluted with sterile water.125 127 128 129 130 133 134 135 136 137 138 184 204 205 206 207 208 210 214 215 254 255 256 (See Dilution under Dosage and Administration.)
Aluminum has been detected as a contaminant in albumin human solutions; aluminum accumulation and associated toxicity (e.g., hypercalcemia, osteodystrophy with associated fracturing osteomalacia, severe progressive encephalopathy) reported in some patients with renal failure receiving albumin human (e.g., via plasmapheresis procedures).101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 140 141 142 143 144 145 215
Manufacturer states that Buminate 25% should not be used in patients with chronic renal impairment because of risk of aluminum accumulation.215
Certain commercially available albumin human preparations are labeled as containing ≤200 mcg/L of aluminum (AlbuRx 5 or 25%, Albutein 5 or 25%, Plasbumin 5, 20, or 25% [low aluminum formulations]).206 211 212 214 247 248 249
Albumin human preparations containing ≤200 mcg/L of aluminum may be preferred in patients at high risk for aluminum toxicity (e.g., neonates, premature infants, geriatric adults, dialysis patients and others with impaired renal function, patients receiving total parenteral nutrition, burn patients).246
Consider potential risks and benefits for the specific patient.208 210 215 Use in pregnant women or during labor and delivery only if clearly needed.204 205 206 207 208 210 211 212 213 214 215 254 255 256 One manufacturer states that there is no evidence for any contraindications specifically associated with reproduction, pregnancy, or the fetus.211 214
Manufacturers of Buminate and Flexbumin state specific pediatric safety studies have not been performed; safety has been demonstrated in children receiving dosage appropriate for child's body weight.208 210 215
Some manufacturers state data regarding use in pediatric patients, including premature infants, are limited.254 255 256 Weigh benefits and risks206 212 and use in pediatric patients only when clearly needed.254 255 256
Has been used as an adjunct to exchange transfusions in the treatment of neonatal hyperbilirubinemia, including hemolytic disease of the newborn (erythroblastosis fetalis).187 204 205 206 208 214 215 Not indicated when neonatal hyperbilirubinemia is treated using phototherapy without exchange transfusions.134 187 (See Neonatal Hyperbilirubinemia under Uses.) Use caution in hypervolemic infants.204 205 214
Some clinicians state albumin human 25% is contraindicated in preterm infants because of risk of intraventricular hemorrhage.311
Risk of aluminum accumulation and associated toxicity in premature neonates.141 142 143 A preparation with low aluminum may be preferred in neonates and premature infants.246 (See Aluminum Content under Cautions)
Increased risk of circulatory overload.204 205 213 214 Use caution in hemodialysis patients or other patients with renal impairment and closely observe for signs of circulatory overload.204 205 211 213 214 215 254 255 256
Common Adverse Effects
Anaphylactoid reactions,254 255 256 fever,204 205 206 207 208 211 210 212 213 214 215 254 255 256 chills,204 205 206 207 208 210 211 212 213 214 215 254 255 256 rash,206 207 212 254 255 256 nausea,206 207 208 210 211 212 214 215 254 255 256 vomiting,206 207 208 210 212 215 254 255 256 tachycardia,206 208 210 212 215 254 255 256 hypotension.206 207 208 210 211 212 214 215 252 254 255 256
Interactions for Albumin Human
Increased risk of atypical reactions (e.g., flushing, hypotension) to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement182
Withhold ACE inhibitors ≥ 24 hours prior to plasma exchange in which large volumes of albumin human are given182
For information on systemic interactions resulting from concomitant use, see Interactions.
Do not mix with parenteral nutrient solutions,257 protein hydrolysates,204 205 206 208 210 212 213 214 215 amino acid solutions,204 205 213 214 or solutions containing alcohol204 205 206 208 210 212 213 214 215 since proteins may precipitate in the solutions.206 212 213 (See Dilution under Dosage and Administration.)
Dextrose–Ringer’s injection combinations
Dextrose–Ringer’s injection, lactated, combinations
Dextrose 2.5, 5, or 10% in water
Ringer’s injection, lactated
Sodium chloride 0.45 or 0.9%
Sodium lactate (1/6) M
Fat emulsion, IV (Intralipid)
Albumin is an important factor in regulation of plasma volume and tissue fluid balance through its contribution to the colloid oncotic pressure of plasma.204 205 206 207 208 210 211 212 213 214 215 254 255 256
IV administration of concentrated albumin human solution causes a shift of fluid from the interstitial spaces into the circulation and a slight increase in the concentration of plasma proteins.204 205 206 207 208 214 215 254 255 256
In the US, albumin human is commercially available as 5, 20, or 25% solutions;204 205 206 207 208 210 211 212 213 214 215 254 255 256 other concentrations (e.g., 4% solutions) are available in other countries.250
When administered IV in well-hydrated patients, each volume of albumin human 20 or 25% solution draws about 2.5 or 3.5 volumes, respectively, of additional fluid into the circulation within 15 minutes, reducing hemoconcentration and blood viscosity.204 205 206 207 208 215
In patients with reduced circulating blood volumes (e.g., from hemorrhage or loss of fluid through exudates or into extravascular spaces), hemodilution persists for many hours.204 205 206 207 208 210 212 215 In patients with normal blood volume, excess fluid and protein are lost from the circulation within a few hours.204 205 206 207 208 210 212 215
Binds and functions as a carrier of intermediate metabolites (including bilirubin), trace metals, some drugs, dyes, fatty acids, hormones, and enzymes, thus affecting the transport, inactivation, and/or exchange of tissue products.20 21 204 205 208 213 226 230 231
Advice to Patients
Advise patient and/or patient's caregiver that albumin human is prepared from pooled human plasma.204 205 206 207 208 210 211 212 213 214 215 254 255 256 Improved donor screening and viral-inactivating procedures used in manufacture of plasma-derived preparations have reduced, but not entirely eliminated, risk of pathogen transmission.204 205 206 207 208 210 211 212 213 214 215 254 255 256 (See Risk of Transmissible Agents in Plasma-derived Preparations under Cautions.)
Importance of discontinuing immediately if allergic symptoms or other severe adverse reactions (e.g., rash, hives, itching, breathing difficulties, coughing, nausea, vomiting, decrease in BP, increased heart rate) occur.254 255 256
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.204 205 206 207 208 210 211 212 213 214 215
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Injection, for IV infusion
Albumin Human 5%
Albumin Human 20%
Albumin Human 25%
AHFS DI Essentials. © Copyright, 2016, American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
Last reviewed: September 28, 2011
Date modified: February 08, 2016
Date published: May 01, 2004
20. Tullis JL. Albumin 1: background and use. (From the Proceedings of the Workshop on Albumin, National Institutes of Health, Bethesda, MD: 1975 Feb 12-14.) JAMA. 1977; 237:355-60.
21. Tullis JL. Albumin 2: guidelines for clinical use. (From the Proceedings of the Workshop on Albumin, National Institutes of Health, Bethesda, MD: 1975 Feb 12-14.) JAMA. 1977; 237:460-3.
24. Thompson WL. Rationale use of albumin and plasma substitutes. Johns Hopkins Med J. 1975; 136:220-5. [IDIS 54331] [PubMed 47936]
30. Ranson JHC, Turner JW, Roses DF et al. Respiratory complications in acute pancreatitis. Ann Surg. 19974; 179:557-66.
36. Food and Drug Administration. Normal serum albumin (human) and plasma protein fraction (human): proposed additional standards. Proposed rule (Docket No. 75-4593). Fed Regist. 1975; 40:7456-60.
37. Food and Drug Administration. Normal serum albumin (human) and plasma protein fraction (human). Final rule (Docket No. 77N-0047). Fed Regist. 1977; 42:27575-84.
101. Milliner DS, Shinaberger JH, Shuman P et al. Inadvertent aluminum administration during plasma exchange due to aluminium contamination of albumin-replacement solutions. N Engl J Med. 1985; 312:165-7. [IDIS 194870] [PubMed 3965935]
102. El Habib R, Eygonnet JP. Aluminum bone disease. BMJ. 1987; 295:1415-6. [PubMed 3121039]
103. Maher ER, Brown EA, Curtis JR et al. Accumulation of aluminium in chronic renal failure due to administration of albumin replacement solutions. BMJ. 1986; 292:306. [PubMed 3080148]
104. Maharaj D, Fell GS, Boyce BF et al. Aluminium bone disease in patients receiving plasma exchange with contaminated albumin. BMJ. 1987; 295:693-6. [IDIS 234639] [PubMed 3117305]
105. Cuthbertson B, McBay WE, Welch AG et al. Aluminium and human albumin solutions. BMJ. 1987; 295:1062. [PubMed 3120871]
106. Koo WWK, Kaplan LA, Horn J et al. Aluminum in parenteral nutrition solution—sources and possible alternatives. J Parenter Enteral Nutr. 1986; 10:591-5.
107. Holberg CP. Aluminum in parenteral products: overview of chemistry concerns and regulatory actions. J Parenter Sci Tech. 1989; 43:127-31.
108. Wilhelm M, Sprenger KBG, Vossas U et al. Aluminum load in chronic intermittent plasma exchange. J Toxicol Clin Toxicol. 1987; 25:209-20. [IDIS 233457] [PubMed 3612899]
109. Köppel C, Baudisch H, Ibe K. Inadvertent metal loading of critically ill patients with acute renal failure by human albumin solution infusion therapy. J Toxicol Clin Toxicol. 1986; 26:337-56.
110. Klein GL. Aluminum in parenteral products: medical perspective on large and small volume parenterals. J Parenter Sci Tech. 1989; 43:120-5.
111. Monteagudo FSE, Cassidy MJD, Folb PI. Recent developments in aluminium toxicology. Med Toxicol Adverse Drug Exp. 1989; 4:1-16. [IDIS 251634] [PubMed 2651849]
112. Quagliaro DA, Geraci VA, Dwan RE et al. Aluminum in albumin for injection. J Parenter Sci Tech. 1988; 42:187-90.
113. Monteagudo F, Wood L, Jacobs P et al. Aluminium loading during therapeutic plasma exchange. J Clin Apheresis. 1987; 3:161-3. [PubMed 3558340]
114. Victor R, Chan AK, Mattoon M. Aluminum contamination in albumin solutions from glass storage. Transfusion. 1988; 28:290-1. [PubMed 3368943]
115. Kelly AT, Short BL, Rains TC et al. Aluminum toxicity and albumin. ASAIO Trans. 1989; 35:674-6. [PubMed 2597561]
116. Klein GL. The aluminum content of parenteral solutions: current status. Nutr Rev. 1991; 49:74-9. [PubMed 1905389]
117. Mousson C, Charhon SA, Ammar M et al. Aluminum bone deposits in normal renal function patients after long-term treatment by plasma exchange. Int J Artif Organs. 1989; 12:664-7. [PubMed 2807593]
118. Olson WP, Kent RS. Aluminum from glass vials contaminates albumin. Transfusion. 1989; 29:86-7. [PubMed 2911868]
119. Klein GL, Herndon DN, Rutan TC et al. Elevated serum aluminum levels in severely burned patients who are receiving large quantities of albumin. J Burn Care Rehabil. 1990; 11:526-30. [PubMed 2286606]
120. Nightingale SL. Dear doctor letter regarding withdrawal of certain plasma products. Rockville, MD: Department of Health and Human Services. Public Health Service. Food and Drug Administration; 1995 Mar 29.
121. Department of Health and Human Services, Food and Drug Administration. Precautionary measures to further reduce the possible risk of transmission of Creutzfeldt-Jakob disease by blood and blood products. 1995 Aug 8. Memorandum.
122. Department of Health and Human Services, Food and Drug Administration. Precautionary measures to further reduce the possible risk of transmission of Creutzfeldt-Jakob disease by blood and blood products. 1995 Aug 8. (Supplemental recommendations to 1987 Nov 25 memorandum on deferral of donors who have received human pituitary-derived growth hormone.)
123. Department of Health and Human Services, Food and Drug Administration. Disposition of products derived from donors diagnosed with, or at known high risk for, Creutzfeldt-Jakob disease. 1995 Aug 8. Memorandum.
124. Forte FJ, Caravone D, Coyne MJ. Albumin dilution as a cause of hemolysis during plasmapheresis. Am J Health-Syst Pharm. 1995; 52:207. [PubMed 12879552]
125. Steinmuller DR. A dangerous error in dilution of 25 percent albumin. N Engl J Med. 1998; 338:1226. [IDIS 403324] [PubMed 9556391]
126. Pierce LR, Gaines A, Varricchio F et al. A dangerous error in dilution of 25 percent albumin. N Engl J Med. 1998; 338:1226-7. [IDIS 403324] [PubMed 9556391]
127. Pierce LR, Gaines A, Varricchio F et al. Hemolysis and renal failure associated with use of sterile water for injection to dilute 25% human albumin solution. Am J Health-Syst Pharm. 1998; 55:1057,1062,1070. [IDIS 405725] [PubMed 9606459]
128. Trissel LA. Hemolysis and renal failure associated with use of sterile water for injection to dilute 25% human albumin solution. Am J Health-Syst Pharm. 1998; Reply. 55:1070.
129. Cohen MR. ISMP medical error report analysis: volume limitations for IV drug infusions using sterile water as diluent. Hosp Pharm. 1998; 33:274,277.
130. Anon. Safety briefs. ISMP Saf Alert. 1998; 3(Jan 14):2.
131. Remington: the science and practice of pharmacy. 19th ed. Gennaro AR, Chairman, Chase GD, Der Marderosian A et al, eds. Easton, PA: Mack Publishing Company; 1995:207- 208.
132. Martin A. Physical pharmacy: physical chemical principles in the pharmaceutical sciences. 4th ed. Philadelphia: Lea & Febiger; 1993:180-6.
133. Food and Drug Administration Center for Biologics Evaluation and Research: Personal communication; 1998 May and Oct.
134. Reviewers’ comments (personal observations).
135. Trissel LA. Handbook on injectable drugs. 15th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; 2009:15-17.
136. Kravath RE. More on dangerous dilution of 25 percent albumin. N Engl J Med. 1998; 339:634. [IDIS 410940] [PubMed 9722440]
137. Pierce LR, Finlayson JS, Epstein JS. More on dangerous dilution of 25 percent albumin. N Engl J Med. 1998; 339:635. [IDIS 410942] [PubMed 9722442]
138. Pierce LR, Gaines A, Finlayson JS et al. Hemolysis and acute renal failure due to the administration of albumin diluted in sterile water. Transfusion. 1999; 39:110-1. [PubMed 9920177]
139. The United States Pharmacopeia, 32nd rev, and The National Formulary, 22nd ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2009: 1436-7.
140. American Academy of Pediatrics Committee on Nutrition. Aluminum toxicity in infants and children. Pediatrics. 1996; 97:413-6. [IDIS 361341] [PubMed 8604282]
141. Klein GL. Aluminum in parenteral solutions revisited—again. Am J Clin Nutr. 1996; 61:449-56.
142. ASCN/ASPEN Working Group on Standards for Aluminum Content of Parenteral Nutrition Solutions. Parenteral drug products containing aluminum as an ingredient or a contaminant: response to the Food and Drug Administration notice of intent and request for information. Am J Clin Nutr. 1991; 15:194-8.
143. Food and Drug Administration. Parenteral drug products containing aluminum as an ingredient or a contaminant; notice of intent and request for information. 21 CFR Ch. 1 [Docket No. 90N-0056]. Fed Regist. 1990; 55:20799-802.
144. Sedman AB, Klein GL, Merritt RJ et al. Evidence of aluminum loading in infants receiving intravenous therapy. N Engl J Med. 1985; 312:1337-43. [PubMed 3921839]
145. Fell GS, Shenkin A, Halls D. Aluminum contamination of intravenous pharmaceuticals, nutrients and blood products. Lancet. 1986; 1:380.
146. Vidor A. Dear customer letter regarding withdrawal of certain lots of Buminate 25%. Lakewood, NJ: Baxter Healthcare Corp; 1997 Mar 13.
147. Vermeulen LC, Ratko TA, Erstad BL et al for the University Hospital Consortium Consensus Exercise on the Use of Albumin et al. A paradigm for consensus: the University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995; 155:373-9. [IDIS 344136] [PubMed 7848020]
148. Erstad BL, Gales BJ, Rappaport WD. The use of albumin in clinical practice. Arch Intern Med. 1991; 151:901-11. [IDIS 282020] [PubMed 1902657]
149. Feigal D. Dear Doctor letter regarding medical administration of albumin or plasma protein fraction to seriously ill patients. Rockville, MD: Food and Drug Administration; 1998 Aug 19.
150. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ. 1998; 316:961-4. [IDIS 404083] [PubMed 9550953]
151. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised trials. BMJ. 1998; 317:235-40. [IDIS 408723] [PubMed 9677209]
152. Offringa M. Excess mortality after human albumin administration in critically ill patients: clinical and pathophysiological evidence suggests albumin is harmful. BMJ. 1998; 317:223-4. [IDIS 408721] [PubMed 9677204]
153. Offringa M. Consider validity, clinical relevance, and applicability of albumin for critically ill patients. BMJ. 1998; 317:343. [IDIS 409067] [PubMed 9685288]
154. Petros A, Schindler M, Pierce C et al. Human albumin administration in critically ill patients: evidence needs to be shown in paediatrics. BMJ. 1998; 317:882. [IDIS 412817] [PubMed 9748194]
155. Nel MR. Human albumin administration in critically ill patients: critical analysis of original studies has to take place. BMJ. 1998; 317:882. [IDIS 412818] [PubMed 9786693]
156. Nadel S, Marriage S, DeMunter C et al. Human albumin administration in critically ill patients: review did not provide recommendations for alternative treatment. BMJ. 1998; 317:882-3.
157. Kaag M, Zoetmulder FAN. Human albumin administration in critically ill patients: more research into proper use of albumin is needed. BMJ. 1998; 317:883.
158. Riordan FAI, Williams A, Thomson APJ. Human albumin administration in critically ill patients: albumin has been used in meningococcal disease. BMJ. 1998; 317:883.
159. Soni N. Human albumin administration in critically ill patients: validity of review methods must be assessed. BMJ. 1998; 317:883-4. [IDIS 412822] [PubMed 9786697]
160. Goodman NW. Human albumin administration in critically ill patients: paper failed to mention earlier review. BMJ. 1998; 317:884. [IDIS 412823] [PubMed 9786699]
161. Beale RJ, Wyncoll DLA, McLuckie A. Human albumin administration in critically ill patients: analysis is superficial and conclusions exaggerated. BMJ. 1998; 317:884. [IDIS 412824] [PubMed 9786698]
162. Frame JD, Moiemem N. Human albumin administration in critically ill patients: statisticians not trained in burns care should not evaluate data. BMJ. 1998; 317:884-5. [IDIS 412825] [PubMed 9786700]
163. Chalmers I. Human albumin administration in critically ill patients: I would not want an albumin transfusion. BMJ. 1998; 317:885. [IDIS 412826] [PubMed 9786701]
164. Lawler PG, Morgan GA. Human albumin administration in critically ill patients: modified editorial might have restrained media response. BMJ. 1998; 317:885. [IDIS 412827] [PubMed 9786702]
165. Shwe KH, Bhavnani M. Human albumin administration in critically ill patients: some patients may benefit. BMJ. 1998; 317:885-6. [IDIS 412828] [PubMed 9786703]
166. Roberts I for the Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: Authors’ response. BMJ. 1998; 317:886.
167. Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol. 1997; 50:693-703. [PubMed 9250267]
168. Berger A. Why albumin may not work. BMJ. 1998; 317:240. [PubMed 9677210]
169. Ginès P, Arroyo V, Vargas V et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunt in cirrhosis with refractory ascites. N Engl J Med. 1991; 325:829-35. [IDIS 285439] [PubMed 1875966]
170. Vermeulen LC, Ratko TA, Matuszewski KA et al. What about plasma? Arch Intern Med. 1995; 155:1817. Reply.
171. Weaver DW, Ledgerwood AM, Lucas CE et al. Pulmonary effects of albumin resuscitation for severe hypovolemic shock. Arch Surg. 1978; 113:387-92. [IDIS 91553] [PubMed 637709]
172. Sibbald WJ, Driedger AA, Wells GA et al. The short-term effects of increasing plasma colloid osmotic pressure in patients with noncardiac pulmonary edema. Surgery. 1983; 93:620-33. [PubMed 6845168]
173. Virgilio RW, Rice RL, Smith DE et al. Crystalloid vs. colloid resuscitation: is one better? A randomized clinical study. Surgery. 1979; 85:129-39. [PubMed 419454]
174. Kassell NF, Peerless SJ, Durward QJ et al. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery. 1982; 11:337-343. [PubMed 7133349]
175. Awad IA, Carter LP, Spetzer RF et al. Clinical vasospasm after subarachnoid hemorrhage: response to hypervolemic hemodilution and arterial hypertension. Stroke. 1987; 18:365-72. [PubMed 3564092]
176. Yamakami I, Isobe K, Yamaura A. Effects of intravascular volume expansion on cerebral blood flow in patients with ruptured cerebral aneurysms. Neurosurgery. 1987; 21:303-9. [PubMed 3670573]
177. Guthrie RD, Hines C. Use of intravenous albumin in the critically ill patient. Am J Gastroenterol. 1991; 86:255-63. [IDIS 278987] [PubMed 1998305]
178. Brecher ME, Owen HG. Washout kinetics of colloidal starch as a partial or full replacement for plasma exchange. J Clin Apheresis. 1996; 11:123-6. [PubMed 8915815]
179. Owen HG, Brecher ME. Partial colloid replacement for therapeutic plasma exchange. J Clin Apheresis. 1997; 12:87-92. [PubMed 9263116]
180. Brecher ME, Owen HG, Bandarenko N. Alternatives to albumin: starch replacement for plasma exchange. J Clin Apheresis. 1997; 12:146-53. [PubMed 9365868]
181. Rock G, Sutton DMC, Freedman J et al for the Canadian Apheresis group. Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange. J Clin Apheresis. 1997; 12:165-9. [PubMed 9483177]
182. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion. 1994; 34:891-4. [PubMed 7940662]
183. Panel on Review of Blood and Blood Derivatives. Fed Regist. 1985; 50:52602-723.
184. Centers for Disease Control and Prevention and Food and Drug Administration. Hemolysis associated with 25% human albumin diluted with sterile water—United States, 1994–1998. MMWR Morb Mortal Wkly Rep. 1999; 48:157-9. [IDIS 421898] [PubMed 10079061]
187. UHC Clinical Practice Advancement Center. Technology assessment: albumin, nonprotein colloid, and crystalloid solutions. Oak Brook, IL: University HealthSystem Consortium; 2000 May.
188. Erstad BL. Concerns with defining appropriate uses of albumin by meta-analysis. Am J Health-Syst Pharm. 1999; 56:1451-4. [IDIS 428690] [PubMed 10428455]
189. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 1999; 39:1160-8. [PubMed 10604241]
190. Medical and Scientific Advisory Council (MASAC), National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders (revised April 2010). MASAC document #195. From National Hemophilia Foundation website.
191. Medical and Scientific Advisory Council (MASAC), National Hemophilia Foundation. MASAC resolution on Creutzfeldt-Jakob disease, new variant CJD, and plasma-derived coagulation products (June 2000). MASAC recommendation #99. From National Hemophilia Foundation website.
192. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). Guidance for industry. Revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jacob disease (CJD) and variant Creutzfeldt-Jacob disease (vCJD) by blood and blood products. May 2010. From FDA website.
193. Ricketts MN, Cashman NR, Stratton EE et al. Is Creutzfeldt-Jakob disease transmitted in blood?. Emerg Infect Dis. 1997 Apr-Jun; 3:155-63.
194. Brown P, Will RG, Bradley R et al. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infectious Dis. 2001; 7:6-16.
195. Centers for Disease Control and Prevention. West Nile virus activity—United States, October 10–16, 2002, and update on West Nile virus infections in recipients of blood transfusions. MMWR Morb Mortal Wkly Rep. 2002; 51:929-31. [PubMed 12403410]
196. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). Guidance for industry. Assessing donor suitability and blood and blood product safety in cases of known or suspected west nile virus infection. June 2005. From FDA website.
197. Medical and Scientific Advisory Council (MASAC), National Hemophilia Foundation. MASAC resolution on reporting of possible west nile virus cases (March 2003). MASAC document #140. From National Hemophilia Foundation website.
198. Harrington T, Kuehnert MF, Kamel H et al. West Nile virus infection transmitted by blood transfusion. Transfusion. 2003; 43:1018-22. [PubMed 12869105]
199. Iwamoto M, Jernigan DB, Gausch A et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003; 348:2196-203. [PubMed 12773646]
200. Chiron. New test developed to screen donated blood for West Nile virus by July 1 deadline. Press release. 2003 June 18.
201. Centers for Disease Control and Prevention. Questions and answers: blood transfusions and organ donations. From the CDC website.
202. Hewitt PE, Llewelyn CA, Mackenzie J et al. Creutzfeldt-Jakob disease and blood transfusion: result of the UK transfusion medicine epidemiological review study. Vox Sang. 2006; 91:221-30. [PubMed 16958834]
204. Talecris Biotherapeutics. Plasbumin-20 (albumin [human] 20%, USP) prescribing information. Research Triangle Park, NC; 2010 Apr.
205. Talecris Biotherapeutics. Plasbumin-25 (albumin [human] 25%, USP) prescribing information. Research Triangle Park, NC; 2010 Apr.
206. Grifols Biologicals. Albutein 25% (albumin [human] USP) sterile, aqueous solution for single dose intravenous administration prescribing information. Los Angeles, CA; 2008 Jul.
207. CSL Behring. Albuminar-25 (albumin [human] USP, 25%) prescribing information. Kankakee, IL; 2008 Jan.
208. Baxter Healthcare Corporation. Flexbumin 25% (albumin [human], USUP, 25% solution in Galaxy single dose container) prescribing information. Westlake Village, CA; 2009 Sep.
210. Baxter Healthcare Corporation. Buminate 5% (albumin [human] USP, 5% solution) prescribing information. Westlake Village, CA; 2009 Sep.
211. CSL Behring. AlbuRx 5 (albumin [human] 5% solution) prescribing information. Kankakee, IL; 2007 Jun.
212. Grifols Biologicals. Albutein 5% (albumin [human] USP) sterile, aqueous solution for single dose intravenous administration prescribing information. Los Angeles, CA; 2008 Jul.
213. Talecris Biotherapeutics. Plasbumin-5 (albumin [human] 5%, USP) prescribing information. Research Triangle Park, NC; 2010 Apr.
214. CSL Behring. AlbuRx 25 (albumin [human] 25% solution) prescribing information. Kankakee, IL; 2007 Jun.
215. Baxter Healthcare Corporation. Buminate 25% (albumin [human], USP, 25% solution) prescribing information. Westlake Village, CA; 2009 Sep.
218. Alderson P, Bunn F, Lefebvre C et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev. 2002; :CD001208. [PubMed 11869596]
219. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2007; :CD000567.
220. Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev. 2008; :CD001319. [PubMed 18253989]
221. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001; 135:149-64. [PubMed 11487482]
222. Finfer S, Bellomo R, Boyce N et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004; 350:2247-56. [PubMed 15163774]
223. Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med. 2004; 32:2029-38. [PubMed 15483411]
224. US Food and Drug Administration (FDA). Safety of albumin administration in critically ill patients. From FDA website. 2005 May 16. Accessed on December 16, 2008.
225. Devlin JW, Barletta JF. Albumin for fluid resuscitation: implications of the Saline versus Albumin Fluid Evaluation. Am J Health Syst Pharm. 2005; 62:637-42. [PubMed 15757887]
226. Mendez CM, McClain CJ, Marsano LS. Albumin therapy in clinical practice. Nutr Clin Pract. 2005; 20:314-20. [PubMed 16207669]
227. McClelland DB. ABC of transfusion. Human albumin solutions. BMJ. 1990; 300:35-7. [PubMed 2105125]
228. Charles A, Purtill M, Dickinson S et al. Albumin use guidelines and outcome in a surgical intensive care unit. Arch Surg. 2008; 143:935-9; discussion 939. [PubMed 18936370]
229. Dubois MJ, Orellana-Jimenez C, Melot C et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med. 2006; 34:2536-40. [PubMed 16915107]
230. Martin GS. A new twist on albumin therapy in the intensive care unit, again. Crit Care Med. 2006; 34:2677-9. [PubMed 16983266]
231. Jardine LA, Jenkins-Manning S, Davies MW. Albumin infusion for low serum albumin in preterm newborn infants. Cochrane Database Syst Rev. 2004; :CD004208.
232. Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2002; :CD001302. [PubMed 12076404]
233. Food and Drug Administration. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices. 21 CFR Part 801. Final rule. (Docket No. 96N-0119) Fed Regist. 1998; 63:50660-704.
234. Food and Drug Administration. Latex-containing devices; user labeling. 21 CFR Part 801. Proposed rule. (Docket No. 96N-0119) Fed Regist. 1996; 61:32617-21.
235. Food and Drug Administration. Natural rubber-containing medical devices; user labeling. 21 CFR Part 801. Final rule. (Docket No. 96N-0119) Fed Regist. 1997; 62:51021-30.
236. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49:2087-107. [PubMed 19475696]
237. Shoham Z, Weissman A, Barash A et al. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril. 1994; 62:137-42. [PubMed 8005278]
238. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008; 90:S188-93.
239. Shalev E, Giladi Y, Matilsky M et al. Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study. Hum Reprod. 1995; 10:1373-6. [PubMed 7593499]
240. Isik AZ, Vicdan K. Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 2001; 97:208-12. [PubMed 11451550]
241. Gokmen O, Ugur M, Ekin M et al. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 2001; 96:187-92. [PubMed 11384805]
242. Isik AZ, Gokmen O, Zeyneloglu HB et al. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study. Eur J Obstet Gynecol Reprod Biol. 1996; 70:179-83. [PubMed 9119100]
243. Duvoux C, Zanditenas D, Hézode C et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002; 36:374-80. [PubMed 12143045]
244. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999; 29:1690-7. [PubMed 10347109]
245. Elwell RJ, Spencer AP, Eisele G. Combined furosemide and human albumin treatment for diuretic-resistant edema. Ann Pharmacother. 2003; 37:695-700. [PubMed 12708949]
246. Talecris Biotherapeutics, Inc., Research Triangle Park, NC: Personal communication.
247. Talecris Biotherapeutics. Plasbumin-5 (low aluminum formulation) (albumin [human] 5%, USP) prescribing information. Research Triangle Park, NC; 2010 Apr.
248. Talecris Biotherapeutics. Plasbumin-20 (low aluminum formulation) (albumin [human] 20%, USP) prescribing information. Research Triangle Park, NC; 2010 Apr.
249. Talecris Biotherapeutics. Plasbumin-25 (low aluminum formulation) (albumin [human] 25%, USP) prescribing information. Research Triangle Park, NC; 2010 Apr.
250. Hollenberg SM, Ahrens TS, Annane D et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004; 32:1928-48. [PubMed 15343024]
251. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36:296-327. [PubMed 18158437]
252. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg. 2004; 139:552-63. [PubMed 15136357]
253. Vincent JL, Wilkes MM, Navickis RJ. Safety of human albumin--serious adverse events reported worldwide in 1998-2000. Br J Anaesth. 2003; 91:625-30. [PubMed 14570782]
254. Octapharma. Albumin (human) 5% for intravenous use only 5% solution prescribing information. Hoboken, NJ; 2008 Aug.
255. Octapharma. Albumin (human) 20% for intravenous use only 20% solution prescribing information. Hoboken, NJ; 2008 Aug.
256. Octapharma. Albumin (human) 25% for intravenous use only 25% solution prescribing information. Hoboken, NJ; 2008 Aug.
257. Lester LR, Crill CM, Hak EB. Should adding albumin to parenteral nutrient solutions be considered an unsafe practice?. Am J Health Syst Pharm. 2006; 63:1656-61. [PubMed 16914638]
258. Venetis CA, Kolibianakis EM, Toulis KA et al. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril. 2011; 95:188-96, 196.e1-3. [PubMed 20579987]
259. Jee BC, Suh CS, Kim YB et al. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest. 2010; 70:47-54. [PubMed 20173327]
260. Nastri CO, Ferriani RA, Rocha IA et al. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet. 2010; 27:121-8. [PubMed 20140640]
261. American Thoracic Society. Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med. 2004; 170:1247-59. [PubMed 15563641]
262. Martin GS, Mangialardi RJ, Wheeler AP et al. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002; 30:2175-82. [PubMed 12394941]
263. Martin GS, Moss M, Wheeler AP et al. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005; 33:1681-7. [PubMed 16096441]
264. Brochard L, Abroug F, Brenner M et al. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med. 2010; 181:1128-55. [PubMed 20460549]
265. Fortin PM, Bassett K, Musini VM. Human albumin for intradialytic hypotension in haemodialysis patients. Cochrane Database Syst Rev. 2010; 11:CD006758. [PubMed 21069691]
266. Knoll GA, Grabowski JA, Dervin GF et al. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. J Am Soc Nephrol. 2004; 15:487-92. [PubMed 14747397]
267. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999; 341:403-9. [PubMed 10432325]
268. Runyon BA. Albumin infusion for spontaneous bacterial peritonitis. Lancet. 1999; 354:1838-9. [PubMed 10584717]
269. Bass NM. Intravenous albumin for spontaneous bacterial peritonitis in patients with cirrhosis. N Engl J Med. 1999; 341:443-4. [PubMed 10432331]
270. Sigal SH, Stanca CM, Fernandez J et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut. 2007; 56:597-9. [PubMed 17369392]
271. Russell JA, Navickis RJ, Wilkes MM. Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. J Cardiothorac Vasc Anesth. 2004; 18:429-37. [PubMed 15365922]
272. Varney KL, Young B, Hatton J. Albumin use in neurosurgical critical care. Pharmacotherapy. 2003; 23:88-92. [PubMed 12523464]
273. Rodling Wahlström M, Olivecrona M, Nyström F et al. Fluid therapy and the use of albumin in the treatment of severe traumatic brain injury. Acta Anaesthesiol Scand. 2009; 53:18-25. [PubMed 18945246]
274. Asplund K. Haemodilution for acute ischaemic stroke. Cochrane Database Syst Rev. 2002; :CD000103. [PubMed 12519536]
275. Frontera JA, Fernandez A, Schmidt JM et al. Clinical response to hypertensive hypervolemic therapy and outcome after subarachnoid hemorrhage. Neurosurgery. 2010; 66:35-41; discussion 41. [PubMed 20023535]
276. Lennihan L, Mayer SA, Fink ME et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage : a randomized controlled trial. Stroke. 2000; 31:383-91. [PubMed 10657410]
277. Palesch YY, Hill MD, Ryckborst KJ et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis. Stroke. 2006; 37:2107-14. [PubMed 16809570]
278. Mayer SA, Solomon RA, Fink ME et al. Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage. Neurosurgery. 1998; 42:759-67; discussion 767-8. [PubMed 9574640]
279. Suarez JI, Shannon L, Zaidat OO et al. Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage. J Neurosurg. 2004; 100:585-90. [PubMed 15070109]
280. Capampangan DJ, Wellik KE, Aguilar MI et al. Does prophylactic postoperative hypervolemic therapy prevent cerebral vasospasm and improve clinical outcome after aneurysmal subarachnoid hemorrhage?. Neurologist. 2008; 14:395-8. [PubMed 19008746]
281. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg. 2001; 72:527-33; discussion 534. [PubMed 11515893]
282. Himpe D. Colloids versus crystalloids as priming solutions for cardiopulmonary bypass: a meta-analysis of prospective, randomised clinical trials. Acta Anaesthesiol Belg. 2003; 54:207-15. [PubMed 14598617]
283. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007; 131:913-20. [PubMed 17356114]
284. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006; 354:2564-75. [PubMed 16714767]
285. Romanelli RG, La Villa G, Barletta G et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol. 2006; 12:1403-7. [PubMed 16552809]
286. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology. 2001; 120:726-48. [PubMed 11179247]
287. Sharma P, Rakela J. Management of pre-liver transplantation patient--part 2. Liver Transpl. 2005; 11:249-60. [PubMed 15719412]
288. Ginès P, Guevara M, Arroyo V et al. Hepatorenal syndrome. Lancet. 2003; 362:1819-27. [PubMed 14654322]
289. Salerno F, Gerbes A, Ginès P et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56:1310-8. [PubMed 17389705]
290. Alessandria C, Ottobrelli A, Debernardi-Venon W et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007; 47:499-505. [PubMed 17560680]
291. Martín-Llahí M, Pépin MN, Guevara M et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008; 134:1352-9. [PubMed 18471512]
292. Nazar A, Pereira GH, Guevara M et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010; 51:219-26. [PubMed 19877168]
293. Cardenas A, Ginès P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol. 2005; 42 Suppl:S124-33.
294. Arroyo V, Fernandez J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis. 2008; 28:81-95. [PubMed 18293279]
295. Brierley J, Carcillo JA, Choong K et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009; 37:666-88. [PubMed 19325359]
296. Polson J, Lee WM, American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology. 2005; 41:1179-97. [PubMed 15841455]
297. Delaney AP, Dan A, McCaffrey J et al. The role of albumin as a resuscitation fluid for patients with sepsis: A systematic review and meta-analysis. Crit Care Med. 2011; 39:386-91. [PubMed 21248514]
298. Han J, Martin GS. Does albumin fluid resuscitation in sepsis save lives?. Crit Care Med. 2011; 39:418-9. [PubMed 21248532]
299. SAFE Study Investigators, Finfer S, McEvoy S et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011; 37:86-96. [PubMed 20924555]
300. Akech S, Ledermann H, Maitland K. Choice of fluids for resuscitation in children with severe infection and shock: systematic review. BMJ. 2010; 341:c4416. [PubMed 20813823]
301. British Committee for Standards in Haematology, Stainsby D, MacLennan S et al. Guidelines on the management of massive blood loss. Br J Haematol. 2006; 135:634-41. [PubMed 17107347]
302. Lawrence A, Faraklas I, Watkins H et al. Colloid administration normalizes resuscitation ratio and ameliorates “fluid creep”. J Burn Care Res. 2010 Jan-Feb; 31:40-7.
303. Choi PT, Yip G, Quinonez LG et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med. 1999; 27:200-10. [PubMed 9934917]
304. Finfer S, Liu B, Taylor C et al. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care. 2010; 14:R185. [PubMed 20950434]
305. Greenhalgh DG. Burn resuscitation: the results of the ISBI/ABA survey. Burns. 2010; 36:176-82. [PubMed 20018451]
306. Faraklas I, Lam U, Cochran A et al. Colloid normalizes resuscitation ratio in pediatric burns. J Burn Care Res. 2011 Jan-Feb; 32:91-7.
307. Pham TN, Cancio LC, Gibran NS et al. American Burn Association practice guidelines burn shock resuscitation. J Burn Care Res. 2008 Jan-Feb; 29:257-66.
308. Groeneveld AB, Navickis RJ, Wilkes MM. Update on the Comparative Safety of Colloids: A Systematic Review of Clinical Studies. Ann Surg. 2011; :. [PubMed 21217516]
309. Greenhalgh DG. Burn resuscitation. J Burn Care Res. 2007 Jul-Aug; 28:555-65.
310. Ginès A, Fernández-Esparrach G, Monescillo A et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996; 111:1002-10. [PubMed 8831595]
311. Robertson J, Shilkofski N, eds. The Harriet Lane handbook: a manual for pediatric house officers. 18th ed. Philadelphia, PA: Elsevier Mosby: 2008.
HID. Trissel LA. Handbook on injectable drugs. 16th ed; Bethesda, MD: American Society of Health-System Pharmacists; 2011:14–16.